Diabetes Drug Leads To, Significant Weight Loss in Those With Obesity, Study Finds. Researchers with Yale University recently published the results of their study in the 'New England Journal of Medicine.'. The diabetes drug tirzepatide was the focus of the study, which also included calorie restriction and 150 minutes of weekly exercise.
Fake Ozempic is putting desperate users at risk — how to spot knockoffsfor use by obese or overweight adults who have at least one weight-related health complication, like Type 2 diabetes, high blood pressure or high cholesterol., sold as Mounjaro, has already been approved for treating Type 2 diabetes since May 2022, but now, patients can be prescribed the drug for chronic weight management.
“In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.” However, the FDA reports that dropping only 5% to 10% of overall body weight can lower the risk of developing heart disease as a result — cue weight management drugs, which can help people lose stubborn pounds when diet and exercise alone fail.
Side effects of the weekly injectable include nausea, vomiting, abdominal discomfort or pain, fatigue, diarrhea, constipation, burping, hair loss, acid reflux and allergic reactions.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Read more »
FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, or tirzepatide.
Read more »
Eli Lilly Stock Jumps on Obesity Drug's FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
FDA approves weight loss drug from Eli Lilly that helped people lose up to 52 poundsThe U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide, which helped dieters lose up to 52 pounds in a recent study.
Read more »